search
Back to results

Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome

Primary Purpose

Cyclic Vomiting Syndrome

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
3mg AZ-010
1mg AZ010
Staccato Placebo
Sponsored by
Alexza Pharmaceuticals, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cyclic Vomiting Syndrome focused on measuring Cyclic Vomiting Syndrome, CVS, Vomiting, Retching, Abdominal migraine, Nausea, Stomach pain, Unexplained vomiting, Functional GI Disorder, CVSHOPE.com, Throwing up, Puking, Dry heaving, Food poisoning, Episodes, Repeated food poisoning

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Adult males and females between 18 and 60 years of age, inclusive at the time of signing the informed consent document.
  • Diagnosis of cyclic vomiting syndrome (CVS) using the Rome IV diagnostic criteria.
  • Otherwise healthy, as determined by the responsible physician, based on a medical evaluation including history, physical examination, vital signs, electrocardiograms (ECGs) and laboratory tests assessed at the screening visit
  • Negative urine tests for selected drugs of abuse and alcohol breath test at Screening.

Exclusion Criteria:

  • Any significant medical or psychiatric condition that could, in the Investigator's opinion, compromise the subject's safety or interfere with the completion of this protocol.
  • Any condition, including the presence of laboratory abnormalities or pulmonary condition, which according to the Investigator places the subject at unacceptable risk if he/she were to participate in the study.
  • A diagnosis of any gastrointestinal disorder other than CVS that in the judgement of the Investigator could compromise the subject's safety or interfere with the interpretation of safety or efficacy data.

Sites / Locations

  • Om Research
  • Axis Clinical Trials
  • Precision Research Institute, LLC
  • University of South Florida
  • Summit Clinical Studies
  • Infinite Clinical Trials
  • Kansas University Medical Center
  • Massachusetts General Hospital
  • Henry Ford Health System
  • Mayo Clinic
  • NY Scientific
  • Temple University Hospital
  • University of Pittsburgh Medical Center
  • New Phase Research & Development, LLC
  • Baylor College of Medicine
  • Pioneer Research Solutions
  • Sante Clinical Research
  • Medical College of Wisconsin

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

1mg AZ010

3mg AZ010

Placebo

Arm Description

Single orally-inhaled dose

Single orally-inhaled dose

Single orally-inhaled dose

Outcomes

Primary Outcome Measures

The number of vomiting/retching events in the 2 hours following treatment.

Secondary Outcome Measures

Number of adverse events as a measure of safety

Full Information

First Posted
November 16, 2020
Last Updated
September 26, 2022
Sponsor
Alexza Pharmaceuticals, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04645953
Brief Title
Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome
Official Title
A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Staccato Granisetron (AZ-010) for the Acute Treatment of Moderate to Severe Cyclic Vomiting Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Completed
Study Start Date
February 11, 2021 (Actual)
Primary Completion Date
July 19, 2022 (Actual)
Study Completion Date
July 19, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alexza Pharmaceuticals, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety study of adult outpatients diagnosed with CVS and experiencing recurring episodes of stereotypical vomiting.
Detailed Description
A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Staccato Granisetron (AZ-010) for the Acute Treatment of Moderate to Severe Cyclic Vomiting Syndrome

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cyclic Vomiting Syndrome
Keywords
Cyclic Vomiting Syndrome, CVS, Vomiting, Retching, Abdominal migraine, Nausea, Stomach pain, Unexplained vomiting, Functional GI Disorder, CVSHOPE.com, Throwing up, Puking, Dry heaving, Food poisoning, Episodes, Repeated food poisoning

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
Double Blind
Allocation
Randomized
Enrollment
151 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1mg AZ010
Arm Type
Experimental
Arm Description
Single orally-inhaled dose
Arm Title
3mg AZ010
Arm Type
Experimental
Arm Description
Single orally-inhaled dose
Arm Title
Placebo
Arm Type
Experimental
Arm Description
Single orally-inhaled dose
Intervention Type
Combination Product
Intervention Name(s)
3mg AZ-010
Intervention Description
Subject will receive a single inhaled dose (3mg)
Intervention Type
Combination Product
Intervention Name(s)
1mg AZ010
Intervention Description
Subject will receive a single inhaled dose (1mg)
Intervention Type
Combination Product
Intervention Name(s)
Staccato Placebo
Intervention Description
Subject will receive a single inhaled dose (Staccato Placebo)
Primary Outcome Measure Information:
Title
The number of vomiting/retching events in the 2 hours following treatment.
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Number of adverse events as a measure of safety
Time Frame
24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adult males and females between 18 and 60 years of age, inclusive at the time of signing the informed consent document. Diagnosis of cyclic vomiting syndrome (CVS) using the Rome IV diagnostic criteria. Otherwise healthy, as determined by the responsible physician, based on a medical evaluation including history, physical examination, vital signs, electrocardiograms (ECGs) and laboratory tests assessed at the screening visit Negative urine tests for selected drugs of abuse and alcohol breath test at Screening. Exclusion Criteria: Any significant medical or psychiatric condition that could, in the Investigator's opinion, compromise the subject's safety or interfere with the completion of this protocol. Any condition, including the presence of laboratory abnormalities or pulmonary condition, which according to the Investigator places the subject at unacceptable risk if he/she were to participate in the study. A diagnosis of any gastrointestinal disorder other than CVS that in the judgement of the Investigator could compromise the subject's safety or interfere with the interpretation of safety or efficacy data.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Larry Carter, PhD
Organizational Affiliation
Alexza Pharmaceuticals, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Om Research
City
Lancaster
State/Province
California
ZIP/Postal Code
93535
Country
United States
Facility Name
Axis Clinical Trials
City
Los Angeles
State/Province
California
ZIP/Postal Code
90036
Country
United States
Facility Name
Precision Research Institute, LLC
City
San Diego
State/Province
California
ZIP/Postal Code
92114
Country
United States
Facility Name
University of South Florida
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Facility Name
Summit Clinical Studies
City
Athens
State/Province
Georgia
ZIP/Postal Code
30607
Country
United States
Facility Name
Infinite Clinical Trials
City
Morrow
State/Province
Georgia
ZIP/Postal Code
30260
Country
United States
Facility Name
Kansas University Medical Center
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Henry Ford Health System
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
NY Scientific
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11235
Country
United States
Facility Name
Temple University Hospital
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19140
Country
United States
Facility Name
University of Pittsburgh Medical Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
New Phase Research & Development, LLC
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37909
Country
United States
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Pioneer Research Solutions
City
Houston
State/Province
Texas
ZIP/Postal Code
77099
Country
United States
Facility Name
Sante Clinical Research
City
Kerrville
State/Province
Texas
ZIP/Postal Code
78028
Country
United States
Facility Name
Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States

12. IPD Sharing Statement

Links:
URL
http://cvshope.com
Description
CVS study web-site

Learn more about this trial

Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome

We'll reach out to this number within 24 hrs